Head to head
West Pharmaceutical Services vs Intuitive Surgical
Side-by-side on the measures that matter, with a plain-English read. Full detail: WST · ISRG
WST
West Pharmaceutical Services
390.30-1.61%
1-year price shape — +52% over the period
Quant Rating C · 87/100
vs
ISRG
Intuitive Surgical
399.05-2.01%
1-year price shape — -28% over the period
Quant Rating D · 15/100
1-year performance, rebased to 100
Intuitive Surgical edges it on the scoreable measures. Intuitive Surgical earns the most per share.
| WST | ISRG | |
|---|---|---|
| Snapshot | ||
| Sector | Medical Instruments & Supplies | -- |
| Last price | 390.30 | 399.05 |
| Change today | -1.61% | -2.01% |
| 1-year return | +51.9% | -27.7% |
| Market cap | $27.19B | $138.33B |
| 52-week range | 223.37 – 437.99 | 328.57 – 603.88 |
| Valuation | ||
| P/E (TTM) | 43.80 | 48.25 |
| P/E percentile, own 5-yr range | 55th | 16th |
| P/B | 9.16 | 8.65 |
| Dividend yield | 0.23% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 6.79 | 7.87 |
| Net profit (TTM) | $473.00M | $2.73B |
| Revenue (TTM) | $3.40B | $11.58B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +8.7% | +21.7% |
| Gross margin | 37.6% | 67.2% |
| Operating margin | 22.5% | 32.3% |
| Net margin | 18.8% | 25.5% |
| Free cash flow (TTM) | $453.40M | $3.60B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 101.5% | 86.7% |
| Insider activity (12mo) | 37 buy / 12 sell | 17 buy / 33 sell |
| Short interest (% of float) | 2.6% | 2.0% |
| Analyst consensus | 100% buy (6) | 100% buy (18) |
| Analyst price target | $478 (+23%) | $516 (+29%) |
| StockVane view | ||
| StockVane Quant Rating | C (87) | D (15) |
| Company | ||
| Employees | 10,800 | 17,021 |
| Founded | 1923 | 1995 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.